Press Releases
EC Approves the AbbVies IMBRUVICA for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
AbbVie a global biopharmaceutical company announced that the EC approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia...
Clinical Trials
Positive VIMPAT monotherapy Phase III trial results presented at European Academy of Neurology Congress
Trial further highlights UCB’s longstanding commitment to enhancing value for people living with epilepsy Data submitted to EMA earlier this year to extend...
Press Releases
EU Grants Approval to Remicade Biosimilar Flixabi
The European Commission (EC) granted marketing authorization in the European Union (EU) for FLIXABI®, an infliximab biosimilar referencing Remicade®i. FLIXABI was developed by Samsung...
Press Releases
AbbVie, Eisai and EA Pharma receive additional approval for new Humira dosing regimen
AbbVie , Eisai Co Ltd. and its subsidiary EA Pharma Co Ltd. announced the additional approval for a new dosing regimen of Humira® Pre-filled...
News
Shire Receives Positive CHMP Opinion in Europe for Revestive for Paediatric Patients with Short Bowel Syndrome
Shire plc announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval...
News
Takeda Receives Positive CHMP Opinion for ADCETRIS as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion...
Press Releases
Merck receives positive CHMP opinion for Zepatier in the EU
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read